[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1971

Drug Treatment in Newly Admitted Schizophrenic Patients

Author Affiliations

Oklahoma City
From the Division of Clinical Pharmacology, Department of Medicine, and the Department of Psychiatry and Behavioral Science, University of Oklahoma Medical Center, Oklahoma City, and Central State Griffin Memorial Hospital, Norman, Okla.

Arch Gen Psychiatry. 1971;25(5):404-409. doi:10.1001/archpsyc.1971.01750170020004
Abstract

The attempt in one hospital to model a drug study after the NIMH nine-hospital collaborative study resulted in a useful modification in which relatively small numbers of newly admitted, acutely exacerbated chronic schizophrenic patients were studied for a period of four weeks. Statistically significant drug: placebo differences were easily detected on most psychiatric and behavioral variables, but not on the psychological performance tasks used. The overall design appears to be suitable for sequential analysis and might provide the basis for an early screening program for antipsychotic drugs in which very small numbers of subjects would be required for relatively short periods of observation. A possible differential drug response favoring thioridazine over chlorpromazine hydrochloride and fluphenazine hydrochloride on several variables was not statistically significant.

×